Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

IntroductionCombining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically “cold” tumors, which are typically less responsive to immunotherapy, are characterized b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alexander A. Pieper, Luke M. Zangl, Dan V. Speigelman, Arika S. Feils, Anna Hoefges, Justin C. Jagodinsky, Mildred A. Felder, Noah W. Tsarovsky, Ian S. Arthur, Ryan J. Brown, Jen Birstler, Trang Le, Peter M. Carlson, Amber M. Bates, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Amy K. Erbe, Paul M. Sondel, Ravi B. Patel, Zachary S. Morris
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
In situ vaccine
cold tumor models
OX40 agonist
CpG – oligonucleotides
radiation therapy
radioimmunotherapy
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/3c1a8a46c1f247d4b0ac7ee7662a9e57
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares